Inhibition of immunoglobulin production by T-614, a new anti-rheumatic drug

T-614 is a new anti-rheumatic drug which has the suppressive effects on cytokine production and lymphocyte proliferation. In phase II study of rheumatoid arthritis (RA) patients, T-614 showed significant improvements in the clinical and laboratory indices. Particularly, serum levels of immunoglobuli...

Full description

Saved in:
Bibliographic Details
Published in:Japanese Journal of Pharmacology 1997, Vol.73 (suppl.1), p.149-149
Main Authors: Tetsuya Yamamoto, Yoshitake Konishi, Mari Mitamura, Yukihiko Aikawa, Keiichi Tanaka
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T-614 is a new anti-rheumatic drug which has the suppressive effects on cytokine production and lymphocyte proliferation. In phase II study of rheumatoid arthritis (RA) patients, T-614 showed significant improvements in the clinical and laboratory indices. Particularly, serum levels of immunoglobulins (Ig) were decreased by the treatment in its early stages. In this study, to confirm the inhibitory effect of T-614 on Ig production, we examined the effect on hyperglobulinemia observed in HgCl_2 -induced autoimmune disease model of Brown Norway rats. As a result, T-614 (30 mg/kg/day, p.o.) significantly reduced the elevation of serum IgE and IgG1 levels induced by HgCl_2 injection, but had no effect on IgG2a level. In addition, the in vitro effects on Ig production by human peripheral mononuclear cells (PBMCs) and ARH-77 cells, a human plasma cell line, were studied. T-614 apparently suppressed the release of IgG and IgM from PBMCs stimulated with pokeweed mitogen. IgG production by ARH-77 cells was also inhibited by T-614 in a dose dependent manner (1-10 μg/ml) without any effect on cell growth. These results indicate that T-614 has immunomodulatory characteristics which may be related to its therapeutic activity in RA.
ISSN:0021-5198